Page 1 of 3
123

Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H, Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1. PMID: 39695574.

View Abstract

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693. ISPOR Europe 2024, November 2024.

View Abstract

Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, Miller B, Jensen I, et al. Real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. ISPOR EU 2024 (Top 5% Finalist).

View Abstract

Haselkorn T, Roca A, Miller B, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, 19–23 November 2024.

Suh M, Mittal L, Brorby G, Pastula S, Vincent M, Proctor D. Epidemiology is critical in advancing cumulative impact assessment (CIA) research: A pilot study in San Antonio, Texas. International Society of Exposure Science, Montreal, Canada, October 2024.

View Abstract

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40th Annual Meeting, Berlin, Germany, August 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain, ISPOR Europe 2024, November 2024.

Seo S, Healey BE, McLin R, Sacks NC, Benson CJ, Citrome L. 2024. Impact of demographics and insurance coverage on schizophrenia treatment and healthcare resource utilization within an integrated healthcare system. Neuropsychiatr Dis Treat 20(Sept 26):1837–1848; doi: 10.2147/NDT.S473492. PMID: 39351585.

View Abstract

DiBiase JF, Scharnetzki E, Edelman E, Reed EK, Helbig P, Rueter J, Miesfeldt S, Frankenfeld CL, et al. 2024. Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing. JNCI Cancer Spectr 8(5):pkae090; doi: 10.1093/jncics/pkae090. PMID: 39312685.

View Abstract

Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I, et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045.

View Abstract
Page 1 of 3
123